BioCardia Reports Third Quarter 2023 Business Highlights and Financial Results
08 nov. 2023 16h11 HE
|
BioCardia, Inc.
SUNNYVALE, Calif., Nov. 08, 2023 (GLOBE NEWSWIRE) -- BioCardia, Inc. [Nasdaq: BCDA], a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases,...
BioCardia to Host Q3 2023 Corporate Update and Financial Results Conference Call on November 8, 2023
01 nov. 2023 17h04 HE
|
BioCardia, Inc.
SUNNYVALE, Calif., Nov. 01, 2023 (GLOBE NEWSWIRE) -- BioCardia®, Inc. [NASDAQ:BCDA], a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases,...
BioCardia Announces Completion of Enrollment in Phase III CardiAMP HF Trial and Plans for CardiAMP HF Trial II
11 oct. 2023 06h00 HE
|
BioCardia, Inc.
SUNNYVALE, Calif., Oct. 11, 2023 (GLOBE NEWSWIRE) -- BioCardia®, Inc. [Nasdaq: BCDA], a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary disease,...
Indaptus Therapeutics Doses First Patient in Second Cohort of Single Dose Ranging Study of Decoy20
19 sept. 2023 08h00 HE
|
Indaptus Therapeutics
NEW YORK, Sept. 19, 2023 (GLOBE NEWSWIRE) -- Indaptus Therapeutics, Inc. (Nasdaq: INDP) (“Indaptus” or the “Company”) announces dosing of the first patient in the second cohort of patients to...
BioCardia Announces Clarification and Next Steps on its Autologous CardiAMP Cell Therapy Programs
06 sept. 2023 07h15 HE
|
BioCardia, Inc.
SUNNYVALE, Calif., Sept. 06, 2023 (GLOBE NEWSWIRE) -- BioCardia®, Inc. [Nasdaq: BCDA], a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary...
BioCardia Announces Interim Efficacy Results in Phase III Pivotal CardiAMP Cell Therapy Heart Failure Trial
05 sept. 2023 07h15 HE
|
BioCardia, Inc.
SUNNYVALE, Calif., Sept. 05, 2023 (GLOBE NEWSWIRE) -- BioCardia®, Inc. [Nasdaq: BCDA], a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary...
BioCardia Reports Second Quarter 2023 Business Highlights and Financial Results
09 août 2023 16h05 HE
|
BioCardia, Inc.
SUNNYVALE, Calif., Aug. 09, 2023 (GLOBE NEWSWIRE) -- BioCardia, Inc. [Nasdaq: BCDA], a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases,...
BioCardia to Host Q2 2023 Financial Results and Corporate Update Conference Call on August 9, 2023
02 août 2023 07h00 HE
|
BioCardia, Inc.
SUNNYVALE, Calif., Aug. 02, 2023 (GLOBE NEWSWIRE) -- BioCardia®, Inc. [NASDAQ:BCDA], a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases,...
BioCardia Announces DSMB Recommendation to Pause New Enrollment in Phase III Pivotal CardiAMP Cell Therapy Heart Failure Trial While Additional Blinded Data is Collected
24 juil. 2023 07h00 HE
|
BioCardia, Inc.
SUNNYVALE, Calif., July 24, 2023 (GLOBE NEWSWIRE) -- BioCardia, Inc. [Nasdaq: BCDA], a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary disease,...
BioCardia Completes Submission of CardiAMP Cell Therapy System in Heart Failure to Japan’s Pharmaceutical Medical Device Agency
05 juil. 2023 07h00 HE
|
BioCardia, Inc.
SUNNYVALE, Calif. , July 05, 2023 (GLOBE NEWSWIRE) -- BioCardia®, Inc. [Nasdaq: BCDA], a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary...